Michael U. Callaghan

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Johannes Oldenburg, Johnny Mahlangu, Benjamin Kim et al. · New England Journal of Medicine · 2017 · 1K citations · Full text

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Johnny Mahlangu, Johannes Oldenburg, Ido Paz‐Priel et al. · New England Journal of Medicine · 2018 · 708 citations · Full text

UPR Pathways Combine to Prevent Hepatic Steatosis Caused by ER Stress-Mediated Suppression of Transcriptional Master Regulators

D. Thomas Rutkowski, Jun Wu, Sung-Hoon Back et al. · Developmental Cell · 2008 · 582 citations · Full text

Reductive Stress, Transcriptional Regulation, Hepatology +14

Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia

Leila Noetzli, Richard Lo, Alisa B. Lee‐Sherick et al. · Nature Genetics · 2015 · 322 citations · Full text

Hematological Malignancy, Medicine, Pathogenesis +8

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel et al. · Blood · 2020 · 270 citations · Full text

Thrombosis, Antibiotics, Pediatric Hematology +15